Dual-acting of Hybrid Compounds - A New Dawn in the Discovery of Multi-target Drugs: Lead Generation Approaches

Author(s): Azizeh Abdolmaleki, Jahan B. Ghasemi

Journal Name: Current Topics in Medicinal Chemistry

Volume 17 , Issue 9 , 2017

Become EABM
Become Reviewer
Call for Editor


Finding high quality beginning compounds is a critical job at the start of the lead generation stage for multi-target drug discovery (MTDD). Designing hybrid compounds as selective multitarget chemical entity is a challenge, opportunity, and new idea to better act against specific multiple targets. One hybrid molecule is formed by two (or more) pharmacophore group’s participation. So, these new compounds often exhibit two or more activities going about as multi-target drugs (mtdrugs) and may have superior safety or efficacy. Application of integrating a range of information and sophisticated new in silico, bioinformatics, structural biology, pharmacogenomics methods may be useful to discover/design, and synthesis of the new hybrid molecules. In this regard, many rational and screening approaches have followed by medicinal chemists for the lead generation in MTDD. Here, we review some popular lead generation approaches that have been used for designing multiple ligands (DMLs). This paper focuses on dual- acting chemical entities that incorporate a part of two drugs or bioactive compounds to compose hybrid molecules. Also, it presents some of key concepts and limitations/strengths of lead generation methods by comparing combination framework method with screening approaches. Besides, a number of examples to represent applications of hybrid molecules in the drug discovery are included.

Keywords: Hybrid molecules, Pharmacophore, Combination Framework, Multi-target, Drug discovery, Medicinal chemistry, Designing multiple ligand.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 12 February, 2017
Page: [1096 - 1114]
Pages: 19
DOI: 10.2174/1568026616666160927151144
Price: $65

Article Metrics

PDF: 93